Table 1.
Summary of patients with PNSs.
| Overall (n = 113) | |
|---|---|
| Age at onset, years, median (IQR) | 60.0 (53.0–65.0) |
| Males, n (%) | 69 (61.1) |
| Antibodies, n (%) | |
| Positive | 90 (79.6) |
| Negative | 23 (20.4) |
| Coexisting antibodies | 14 (12.4) |
| Cancers, n (%) | |
| Detected | 81 (71.7) |
| Negative | 32 (28.3) |
| Oncotherapies, n (%) | 42 (37.2) |
| Monotherapy | |
| Surgery | 15 (13.3) |
| Chemotherapy | 14 (12.4) |
| Radiotherapy | 1 (0.9) |
| Combined therapies* | 12 (10.6) |
| Unknown | 18 (15.9) |
| First-line immunotherapies, n (%) | |
| Steroids monotherapy | 19 (16.8) |
| IVIG monotherapy | 10 (8.9) |
| Steroids combined with IVIG | 12 (10.6) |
| Outcomes, n (%) | |
| Death | 34 (30.1) |
| Deterioration | 10 (8.8) |
| Stabilization | 15 (13.3) |
| Remission | 47 (41.6) |
| Unknown | 7 (6.2) |
IQR, interquartile range; IVIG, intravenous immunoglobulin; PNS, paraneoplastic neurologic syndrome.
*Any combination of surgery, chemotherapy, and radiotherapy.